Kornimate/medical-research-clean huggingface dataset:
the belgian diabetes in pregnancy follow-up study

Conditions: Gestational Diabetes; Type2 Diabetes; Obesity

Summary: gestational diabetes (gdm) is a form of diabetes that develops during pregnancy. gdm is associated with increased risks for pregnancy complications such as macrosomia s and preterm delivery. women with a history of gdm have a high risk to develop a type 2 diabetes (t2dm) within the next ten years after delivery. the children are also at increased risk of developing obesity and t2dm later in life. studies are needed to find more accurate predictors for the metabolic risk later in life. this will help to individualize the follow-up and to develop tailored prevention strategies in women and offspring with a history of gdm. in this research project we will therefore investigate how the long-term metabolic risk can more accurately be predicted in a follow-up cohort of the 'belgian diabetes in pregnancy study' (bedip-n). we will study the relationship between maternal weight, degree of body fat and degree of hyperglycaemia in pregnancy on the long-term metabolic risk of 375 women and offspring pairs 3-7 years after the delivery across different gestational glucose tolerance groups based on the 2013 who criteria in pregnancy. in addition, we will study whether a promising new biomarker, glycated cd59, is a good predictor for the long-term metabolic risk.


Eligibility criteria:
inclusion criteria: * mothers who participated in the completed bedip-n study and received both the gct as the ogtt during pregnancy * offspring born at the time of participation in the bedip-n study exclusion criteria: * mothers: * current pregnancy * treatment that influences glycaemic status such as high dose corticoids. * history of bariatric surgery * gastro-intestinal surgery changing the absorption of glucose (billroth ii) * a normal study visit will not be possible (incompliance, psychiatric problems...) * diagnosed with type 1 diabetes or the presence of auto-immune antibodies for type 1 diabetes offspring: * treatment that influences glycaemic status such as high dose corticoids. * a normal study visit will not be possible (incompliance, psychiatric problems...) * diagnosed with type 1 diabetes or the presence of auto-immune antibodies for type 1 diabetes
long-term outcomes of conical tapered stems in cementless total hip arthroplasty due to congenital hip pathologies

Conditions: Dysplasia; Hip; Prosthesis Survival

Summary: a retrospective consecutive population of patients treated with conical tapered stems in cementless total hip arthroplasty for osteoarthritis due to congenital hip pathologies will be selected. the aim of this retrospective study is to evaluate the long-term clinical and radiographic results of this implant and the survival rates in such a specific cohort.

congenital hip pathologies may severely alter the local anatomy of the hip, making total hip arthroplasty (tha) due to osteoarthritis after congenital hip pathologies challenging. while it seems that congenital hip pathologies did not significantly influence the outcomes when compared to tha after osteoarthritis, the choice of implant was demonstrated to impact the survival rates of the tha after congenital hip pathologies. to date, no guidelines exist about the correct choice of hip implant in congenital hip pathologies: only mid-term case series are available. conical tapered stems have been frequently suggested for the most difficult cases. the aim of this study is to describe the survival rates and the long-term clinical and radiological outcome of conical tapered stems in thas after congenital hip pathologies.

Eligibility criteria:
inclusion criteria: * symptomatic hip osteoarthritis due to congenital hip pathologies * consecutive population with a minimum follow-up of 2 years * cementless total hip arthroplasty with conical tapered stem * pre-operative planning using ct * complete clinical and radiographic assessment exclusion criteria: * other type of hip osteoarthritis * other type of implants * inadequate pre-operative planning (eg: no ct) * incomplete clinical and radiographic assessment
association between euploid embryo grade and maternal age

Conditions: Fertility

Summary: background: advanced maternal age (ama) is associated with a reduction in live birth rate (lbr) after art cycles. the main reason for this reduction is the lower number of oocytes aspirated, the number of developing embryos and the low number of euploid embryos available for transfer. the impact of age on success rates after the transfer of an euploid embryo has been a matter of discussion, with a recent meta-analysis showing a reduction in lbr after the transfer of an euploid blastocyst to women of ama (1). there could be many reasons for this reduced lbr but they can be categorized into two broad categories - the uterus (including the mother's health) and the embryo (including the oocyte and the sperm). it is possible that factors associated with reduced embryo quality would manifest in a lower embryo grade.

objective: to study if there is an association between advanced maternal age and lower embryo grading of euploid embryos. hypothesis: advanced maternal age is associated with a lower embryonic grade in euploid embryos. study design: this is a retrospective cross-sectional study of euploid embryos from patients who have completed ivf with pgt-a testing at a fertility clinic in the prelude network (us sites only). a comparison of embryo grade between different age groups (\<35, 40+) will be done after controlling for baseline demographic characteristics.

Eligibility criteria:
inclusion criteria: * patients who have completed ivf egg retrieval with pgt-a testing at a fertility clinic in the prelude network (us clinics, excluding nyu) * pgt biopsy was conducted in 2023, * pgt biopsy was performed on blastocyst stage embryo, * pgt-a result is euploid. exclusion criteria: * pgt-a result is mosaic, * embryos in which pgt-m was done and were found to be carriers of the mutation, * embryos in which pgt-sr was done and were found to be carriers of the structural rearrangement.

Keywords: advanced maternal age embryo grade
applying novel technologies and methods to self-regulation: behavior change tools for smoking and binge eating

Conditions: Smoking; Binge Eating; Behavior

Summary: this study will evaluate the extent to which we can engage and manipulate putative targets within the self-regulation domain within and outside of laboratory settings in samples of smokers and overweight/obese individuals with binge eating disorder. this is the fourth phase of a study that aims to identify putative mechanisms of behavior change to develop an overarching "ontology" of self-regulatory processes.


Eligibility criteria:
inclusion criteria: * understand english sufficiently to provide informed consent * right-handed * normal or corrected-to-normal vision and no color blindness * interest in engaging with laddr to modify self-regulatory behavior additional inclusion criteria for smoking sample: * smoke 5 or more tobacco cigarettes/day for past year * bmi greater than or equal to 17 and less than 27 additional inclusion criteria for binge eating sample: * bmi greater than or equal to 27 and less than 45 * weight limit of 350 lbs * non-smoking (defined as no cigarettes in past 12 months-this includes former and never smokers) exclusion criteria: * significant medical illness * history of mental disorder due to a medical condition * lifetime history of major psychotic disorders (including schizophrenia and bipolar disorder) * current use of any medication for psychiatric reasons (including stimulants and mood stabilizers) additional exclusion criteria for binge eating sample: * lost weight in recent past (\>10 pounds in past 6 months) * currently in a weight-loss program (e.g., weight watchers, jenny craig) * currently on a special diet for a serious health condition * current engagement in psychotherapy for binge eating disorder additional exclusion criteria for smoking sample: * binge eating behavior * current engagement in psychotherapy for smoking behavior
endocardial stem cells approach efficacy

Conditions: Myocardial Ischemia

Summary: the primary objective of this study is to test that endocardial stem cells implantation in patients who have cad, low ejection fraction and signs of hf without possibility of cabg and pci or despite on previous revascularization improves long-term survival compared to med alone


Eligibility criteria:
inclusion criteria: * men and women who are not of childbearing potential * age 21-75 years. * patients with cad, nyha and ccs angina iii-iv functional class * lvef less than 35% measured by echocardiography or spect within three months of study entry * unsuitable for initial or repeated conventional revascularization (cabg or pci) exclusion criteria: * failure to provide informed consent. * plan for pci or cabg. * non-cardiac illness with a life expectancy of less than 3 year. * conditions/circumstances likely to lead to poor treatment adherence (e.g., history of poor compliance, alcohol or drug dependency, psychiatric illness, no fixed abode). * previous heart, kidney, liver, or lung transplantation. * current participation in another clinical trial in which a patient is taking an investigational drug or receiving an investigational medical device. * recent acute myocardial infarction (ami) within 90 days of study entry * successful coronary revascularization (сabg or pci) within 12 months of study enrollment * history of moderate to severe aortic stenosis or prosthetic aortic valve * permanent atrial fibrillation * thrombosis in lv, based on echocardiography data
long-term release of fluoride formed on enamel by fluoride gel or varnish to biofilm fluid

Conditions: Dental Caries

Summary: the anticaries effect of professional fluoride application has been associated with the formation of calcium fluoride-like products ("caf2") on dental surface, which may function as a slow release fluoride reservoir. among professional fluoride products, fluoride gel and varnish are the most important, and have different soluble fluoride concentrations, phs and vehicles. although the concentration of fluoride formed on enamel after the use of both is similar, the retention of these reaction products is unknown. also, it is unknown the capacity of these reservoirs to enhance dental biofilm fluid with fluoride. moreover, the effect of the varnish application time on these parameters is unknown. therefore, the aim of this study is to compare the capacity of fluoride gel and varnish to form fluoride reservoirs on enamel and increase dental biofilm fluid fluoride concentration with time. rapid biofilm-forming individuals will be selected to participate and divided into 4 experimental groups: 1. negative control: no treatment; 2. varnish 4 hours: fluoride varnish will be applied and kept on teeth for 4 hours; 3. varnish 24 h: fluoride varnish will be applied on teeth and kept for 24 h; and 4. gel: fluoride gel will be applied on teeth. microbiopsies of enamel will be obtained by a microbiospy technique to assess fluoride concentration before, 7 and 28 days after the treatments. dental biofilm will be collected before and 3, 7, 14 and 28 days after treatments. fluoride concentration on enamel and in the biofilm fluid will be determined by an ion-specific electrode. data will be analyzed statistically comparing the groups and collection times.


Eligibility criteria:
inclusion criteria: * good general health * good oral health * at least 5 teeth in each hemiarch * all 4 superior incisors in the mouth * rapid biofilm forming exclusion criteria: * pregnancy * intake of medication that reduces salivary flow * chronic diseases * smokers * orthodontic appliances * dental prosthesis * allergy to fluoride varnish components

Keywords: fluoride biofilm fluid calcium fluoride topical
the origin of phantom limb sensation and phantom limb pain in amputees

Conditions: Exposure to Infrared Radiation

Summary: with the far infrared ray applied to the 'phantom limbs' in amputees and the corresponding normal legs in healthy subjects, the sensation of (phantom) limb will be assessed for each subject using the techniques of fmri and meridian response.

this project will investigate two main hypotheses based on our previous studies on phantom limb sensation and phantom limb pain. the first hypothesis states that phantom limb sensation and phantom limb pain both correlate with the 'phantom limb', while the second one maintains that the phantom limb can interact with the patient's body by means of the meridian system. with the far infrared ray applied to the 'phantom limbs' in amputees and the corresponding normal legs in healthy subjects, the sensation of (phantom) limb will be assessed for each subject using the techniques of fmri and meridian response. by analyzing the data collected from both groups, the investigators expect both hypotheses will be supported by the results of experiments in this project.

Eligibility criteria:
inclusion criteria: * amputees: at least one arm or one leg amputated * healthy subjects: healthy person under 30 years old exclusion criteria: * with mental diseases
pharmacokinetics of rlx030 in subjects with mild, moderate and severe hepatic impairment compared to healthy subjects

Conditions: Hepatic Impairment

Summary: this study will assess the pharmacokinetics of rlx030 during and after administration in subjects with mild to severe hepatic impairment and matched healthy control subjects. 20 to 24 patients and 20 to 24 healthy subjects will be enrolled.


Eligibility criteria:
inclusion criteria: * all subjects: • female subjects must be of non-child bearing potential or use an effective method of contraception and sexually active males must use a condom during intercourse while taking the drug and for 5 half-lives after stopping treatment * subjects with hepatic impairment: * subjects must have either mild, moderate or severe hepatic impairment exclusion criteria: * all subjects * hepatic impairment due to non-liver disease * use of other investigational drugs at time of enrollment * history of malignancy of any organ system * donation or loss of 400 ml or more of blood or plasma within 8 weeks prior to initial dosing * hemoglobin levels below 10.0 g/dl at screening or baseline * subjects with hepatic impairment: * presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk * treatment with any cytostatic drug, vasodilator, autonomic alpha blocker or b2 agonist * any surgical or medical condition other than hepatic impairment which might significantly alter the distribution or excretion of drugs other protocol-defined inclusion/exclusion criteria may apply.

Keywords: hepatic impairment healthy volunteers rlx030 pharmacokinetics
hemodynamic protection of preoperative ondansetron 15 minutes before spinal anaesthesia in caesarean section

Conditions: Hypotension; Nausea; Vomiting

Summary: spinal anaesthesia for caesarean section is the most commonly used anaesthetic choice in caesarean deliveries. this is usually associated with maternal hypotension and other adverse side effects. prophylactic intravenous administration of ondansetron immediately and 5 minutes preoperatively have shown to provide a protective effect against hypotension while other studies have shown little effect on the incidence of blood pressure drop in healthy parturients. the investigators will study the effect of different doses and timing of intravenous ondansetron in full term obstetric patients undergoing elective lower segment caesarean section under spinal anaesthesia on the incidence and severity of hypotension and other adverse side effects in healthy parturients having the standard intrathecal plain bupivacaine and fentanyl.

this prospective randomized double-blind placebo-controlled study will include 150 american society of anaesthesiologist physical status grade i (asa i) pregnant women scheduled for elective caesarean delivery under spinal anaesthesia. patients will be randomly allocated into three groups (n = 50) to receive intravenous ondansetron 4mg in 10 ml normal saline (group o4), 6 mg in 10 ml normal saline(group o6), or placebo of 10 ml normal saline (group c), all 15-20 minutes before spinal anaesthesia. hemodynamic variables and other adverse effects will be assessed at 16 time points intraoperatively. those variables include blood pressure, heart rate, oxygen saturation, nausea, vomiting, electrocardiographic changes, skin flushing, discomfort or pruritus, perioperative vasopressor requirements and patients' satisfaction. participants will be randomly allocated preoperatively as per randomizer.org software and will be blinded from other anaesthetists performing the spinal block and following patients intraoperatively.

Eligibility criteria:
inclusion criteria: * patients who received spinal anesthesia for elective cesarean sections and meet the american society of anesthesiologist's (asa) patient status classification i or ii. exclusion criteria: * patients asa patient status classification iii, iv or v * emergent cesarean sections * multiple parities (twins/triplets) * more than 1,000 ml blood loss * more than 6 mg ondansetron administered * patients presenting with a cardiac history (coronary artery disease, myocardial infarction, congestive heart failure, murmur, mitral valve prolapse/regurgitation, dysrhythmias, aortic stenosis/regurgitation) * patients presenting with preeclampsia * patients presenting for cesarean section with epidural due to failure to progress.

Keywords: ondansetron hypotension nausea and vomiting cesarean section
avatar-mediated therapy versus cognitive behavioural therapy for persisting experiences of hearing voices

Conditions: Auditory Hallucination; Psychotic Disorders; Schizophrenia and Related Disorders

Summary: the aim of this study is to compare the effects of a new psychological therapy, avatar therapy, to the current standard therapy, cognitive behavioural therapy (cbt), in improving outcomes in people living with psychotic disorders who have persisting experiences of hearing voices (auditory verbal hallucinations, avhs).

continually hearing critical, abusive or threatening voices (auditory verbal hallucinations, avhs) is a major persisting and disabling symptom of psychotic disorders such as schizophrenia. current treatments have universally had only modest impact. in preliminary trials, a brief digitally supported treatment, using avatars to recreate avhs during therapy, has produced some of the largest reductions in avh severity seen to date. to definitively test the superiority of this innovative treatment, amethyst is a randomised controlled trial comparing avatar therapy to current recommended best practice treatment, cbt, for medication-resistant avhs.

Eligibility criteria:
inclusion criteria: * schizophrenia-related disorder or a mood disorder with psychotic symptoms diagnosis confirmed using the structured clinical interview for dsm (scid) * experiencing current auditory verbal hallucinations as measured by the positive and negative syndrome scale (panss) item p3 ≥ 4 * auditory verbal hallucinations present for at least one year * avhs include significant negative content (psyrats item 6 ≥ 2) and/or avhs are distressing (psyrats item item 9 ≥ 2) * current treatment with antipsychotic medication, or has been treated with antipsychotic medication in the past, with at least two different antipsychotic compounds, and these have been discontinued due to insufficient treatment response and/or poor tolerability. * access to the internet and a computer or other device on which videoconferencing software can be used * sufficient fluency in english for meaningful participation * age 18 or over * ability to give informed consent exclusion criteria: * auditory verbal hallucinations attributable to a primary substance use disorder or organic disorder * estimated full scale iq \< 70 (using the test of premorbid functioning, topf) * within the last month or planned at the time of intake: a change of antipsychotic medication, * current or within the past 3 months receipt of individual psychological therapy for hearing voices, or receipt of electro-convulsive therapy or other brain stimulation treatment; * avhs in a language not spoken by the therapists.

Keywords: auditory verbal hallucinations psychosis schizophrenia psychological therapy cognitive behavior therapy avatar therapy virtual reality telehealth
effectiveness of convalescent immune plasma therapy

Conditions: Acute Respiratory Distress Syndrome

Summary: the aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe covid-19 patients with ards.

the aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe covid-19 patients followed up in critical care unit.

Eligibility criteria:
inclusion criteria clinical diagnosis of covid-19 exclusion criteria age lower than 18 lower plasma iga levels pao2/fio2 higher than 300 mmhg spo2 higher than 90
non-invasive evaluation of the predictive value of ceus and swe in aclf, renal failure and hepatorenal syndrome

Conditions: Kidney Failure, Acute

Summary: evaluation of non-invasive prognostic parameters in patients developing aclf and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (tips). patients are cared according to the local standardized follow up program. clinical and laboratory data from standard patient care are evaluated for potential prognostic value.

nectar consists of patients with aclf and renal failure with and without receiving transjugular intrahepatic portosystemic shunt (tips) at the department of internal medicine i, university of bonn, germany and receiving a structured routine evaluation and follow up program. the diagnosis of cirrhosis was based on clinical, hemodynamic and biochemical parameters, and ultrasound and/or biopsy criteria.

Eligibility criteria:
inclusion criteria: * all patients with portal hypertension and kidney failure exclusion criteria: * no consent, no kidney failure, no portal hypertension

Keywords: transjugular intrahepatic portosystemic shunt (tips) non-invasive assessments circulating biomarkers transthoracic echocardiography (tte) with speckle-tracking elastography contrast-enhanced ultrasound computer tomography scan (ct-scan) magnetic resonance imaging (mri) urine biomarker